Literature DB >> 15230340

The interaction of the diltiazem with oral and intravenous cyclosporine in rats.

Sule Kalkan1, Mukaddes Gumustekin, Oguz Aygoren, Yesim Tuncok, Ayse Gelal, Hulya Guven.   

Abstract

This study investigated the effect of diltiazem on the bioavailability of oral and intravenous cyclosporine (CsA) in rats. While control rats received normal saline, experimental groups received 60 or 90 mg/kg diltiazem orally for 3 days. Each group divided into 2 equal groups that received a single oral dose or i.v. injection of CsA. Pharmacokinetic parameters were analyzed by nonparametric analysis of variance. Pretreatment with 60 or 90 mg/kg diltiazem decreased the area under the blood CsA concentration-time curve (AUC) of oral CsA compared to control group (54.5% and 65.5% for AUC(0-24), 57.6% and 62.2% for AUC(0-infinity), respectively, p<0.05). Mean CsA maximum concentration (Cmax) decreased from 0.4 +/- 0.1 microg/ml to 0.1 +/- 0.0 microg/mL in rats pretreated with 90 mg/kg diltiazem (p<0.05). The absolute bioavailability after oral administration (F(p.o.)) in the 60 or 90 mg/kg diltiazem groups were lower than the control group (9.6% and 8.5% versus 22.6%). Pretreatment with 90 mg/kg but not 60 mg/kg of diltiazem increased the AUC(0-infinity), elimination half-life (t1/2) of intravenous CsA (116.0%, 219.2%, respectively, p<0.05) and decreased the intravenous CsA clearence (CL(i.v.)) (62.9%, p<0.05). Diltiazem decreased the bioavailability of oral CsA, while it increased the bioavailability of intravenous CsA. One must consider this interaction when administering oral or intravenous CsA concomitantly with diltiazem.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15230340     DOI: 10.1007/BF03190586

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  34 in total

1.  Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.

Authors:  D Sutton; A M Butler; L Nadin; M Murray
Journal:  J Pharmacol Exp Ther       Date:  1997-07       Impact factor: 4.030

2.  Increased cyclosporine blood concentrations due to verapamil administration.

Authors:  T G Maggio; D W Bartels
Journal:  Drug Intell Clin Pharm       Date:  1988-09

3.  Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole.

Authors:  Vincent J Wacher; Susan Wong; Harrison T Wong
Journal:  J Pharm Sci       Date:  2002-01       Impact factor: 3.534

4.  Physiologic modeling of cyclosporin kinetics in rat and man.

Authors:  A Bernareggi; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

5.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily.

Authors:  J Combalbert; I Fabre; G Fabre; I Dalet; J Derancourt; J P Cano; P Maurel
Journal:  Drug Metab Dispos       Date:  1989 Mar-Apr       Impact factor: 3.922

6.  Diltiazem does not always increase blood cyclosporin concentration.

Authors:  T E Jones; R G Morris
Journal:  Br J Clin Pharmacol       Date:  1996-11       Impact factor: 4.335

7.  Effect of atropine on gastrointestinal motility and the bioavailability of cyclosporine A in rats.

Authors:  R F Quijano; N Ohnishi; K Umeda; F Komada; S Iwakawa; K Okumura
Journal:  Drug Metab Dispos       Date:  1993 Jan-Feb       Impact factor: 3.922

8.  Tissue distribution, disposition, and metabolism of cyclosporine in rats.

Authors:  O Wagner; E Schreier; F Heitz; G Maurer
Journal:  Drug Metab Dispos       Date:  1987 May-Jun       Impact factor: 3.922

9.  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.

Authors:  J C Kolars; P Schmiedlin-Ren; J D Schuetz; C Fang; P B Watkins
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

10.  Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients.

Authors:  M R First; T J Schroeder; J W Alexander; G W Stephens; P Weiskittel; S A Myre; A J Pesce
Journal:  Transplantation       Date:  1991-02       Impact factor: 4.939

View more
  2 in total

1.  Combination therapy with diltiazem plus CsA/MMF/Pred or CsA/Aza/Pred triple immunosuppressive regimens for use in clinical kidney transplantation in Northwestern China.

Authors:  Yong Song; Wujun Xue; Puxun Tian; Xiaoming Ding; Xiaoming Pan; Hang Yan; Jun Hou; Xinshun Feng; Heli Xiang; Xiaohui Tian; Gaoping Qin; Xiaohu Fan
Journal:  Eur J Clin Pharmacol       Date:  2011-01-29       Impact factor: 2.953

2.  The effects of diltiazem in renal transplantation patients treated with cyclosporine A.

Authors:  Wujun Xue; Yong Song; Puxun Tian; Xiaoming Ding; Xiaoming Pan; Hang Yan; Jun Hou; Xinshun Feng; Heli Xiang; Xiaohui Tian
Journal:  J Biomed Res       Date:  2010-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.